I do not think they need permission, they are providers to research, they are collecting it from whole blood, they do not produce it, neither use it on any patented way by xoma.
Quite neat.
Regarding the Crohn's research. Bax is not interested in spending money in bpi (my view from long ago), Bax does not get many subjects, the subjects are going to Antegren research by Elan/Biogen a better drug with good results in phase II (a real phase II, by the way, it had about 200 subjects with several dosing regimes and double blind ramdomized placebo control group and statistical significance achieved) researchers and subjects know that, why go to an open label small trials without any clinical basis (theoretical basis, yes)and little money available.
Joslin is funded by xoma, therefore expect slow moves, xoma is wasting money (as usual) on Milenium dust bin leftover molecules. |
